专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2005082004A2 RATIONALLY DESIGNED ANTIBODIES HAVING A DOMAIN-EXCHANGED SCAFFOLD 审中-公开
标题翻译：具有域交换SCAFFOLD的方案设计抗体
公开(公告)号：WO2005082004A2
公开(公告)日：2005-09-09
申请号：PCT/US2005/005879
申请日：2005-02-22
申请人： ALEXION PHARMACEUTICALS, INC. , BOWDISH, Katherine, S. , FREDERICKSON, Shana , RENSHAW, Mark , MARUYAMA, Toshiaki , ORENCIA, Cecilia
发明人： BOWDISH, Katherine, S. , FREDERICKSON, Shana , RENSHAW, Mark , MARUYAMA, Toshiaki , ORENCIA, Cecilia
摘要： Domain-exchanged antibodies having CDR regions replaced or fused with biologically active peptides are described. Flanking sequences may optionally be attached at one or both the carboxy-terminal and amino-terminal ends of the peptide in covalent association with adjacent framework regions. Compositions containing such modified domain-exchanged antibodies are useful in therapeutic and diagnostic modalities.
摘要翻译：描述了具有被替换或与生物活性肽融合的CDR区的域交换的抗体。侧翼序列可以任选地在肽的羧基末端和氨基末端的一个或两个连接，与相邻构架区共价结合。含有这种修饰的结构域交换抗体的组合物可用于治疗和诊断方式。

2. 发明申请

WO2005060642A2 RATIONALLY DESIGNED ANTIBODIES 审中-公开
标题翻译：方案设计抗体
公开(公告)号：WO2005060642A2
公开(公告)日：2005-07-07
申请号：PCT/US2004/041946
申请日：2004-12-15
申请人： ALEXION PHARMACEUTICALS, INC. , BOWDISH, Katherine, S. , FREDERICKSON, Shana , RENSHAW, Mark , ORENCIA, Cecilia
发明人： BOWDISH, Katherine, S. , FREDERICKSON, Shana , RENSHAW, Mark , ORENCIA, Cecilia
IPC分类号： A61K39/395 , C07H21/04 , C07K14/505 , C07K14/52 , C07K16/00 , C07K16/12 , C07K16/18 , C07K16/46
CPC分类号： C07K16/00 , A61K2039/505 , C07K14/505 , C07K14/524 , C07K16/005 , C07K16/12 , C07K16/1282 , C07K16/18 , C07K16/46 , C07K2317/21 , C07K2317/55 , C07K2317/565 , C07K2317/567 , C07K2317/74 , C07K2318/10 , C07K2319/00 , C07K2319/30
摘要： Antibodies or fragments thereof having CDR regions replaced or fused with biologically active peptides are described. Flanking sequences may optionally be attached at one or both the carboxy-terminal and amino-terminal ends of the peptide in covalent association with adjacent framework regions. Compositions containing such antibodies or fragments thereof are useful in therapeutic and diagnostic modalities.
摘要翻译：描述了具有替换或与生物活性肽融合的CDR区的抗体或其片段。侧翼序列可以任选地在肽的羧基末端和氨基末端的一个或两个连接，与相邻构架区共价结合。含有此类抗体或其片段的组合物可用于治疗和诊断方式。

3. 发明申请

WO2004108078A2 RATIONALLY DESIGNED ANTIBODIES 审中-公开
标题翻译：原理设计的抗体
公开(公告)号：WO2004108078A2
公开(公告)日：2004-12-16
申请号：PCT/US2004/016574
申请日：2004-05-26
申请人： ALEXION PHARMACEUTICALS INC. , BOWDISH, Katherine, S. , FREDERICKSON, Shana , RENSHAW, Mark , ORENCIA, Cecilia
发明人： BOWDISH, Katherine, S. , FREDERICKSON, Shana , RENSHAW, Mark , ORENCIA, Cecilia
IPC分类号： A61K
CPC分类号： C07K16/1282 , C07K2317/21 , C07K2317/55 , C07K2317/565 , C07K2318/10
摘要： Antibodies or fragments thereof having at least two CDR regions replaced or fused with biologically active peptides are described. Compositions containing such antibodies or fragments thereof are useful in therapeutic and diagnostic modalities.
摘要翻译：描述了具有至少两个CDR区被生物活性肽替代或融合的抗体或其片段。含有此类抗体或其片段的组合物可用于治疗和诊断方式。

4. 发明申请

WO2003025202A3 ENGINEERED TEMPLATES AND THEIR USE IN SINGLE PRIMER AMPLIFICATION 审中-公开
公开(公告)号：WO2003025202A3
公开(公告)日：2003-03-27
申请号：PCT/US2002/029889
申请日：2002-09-19
申请人： ALEXION PHARMACEUTICALS, INC. , BOWDISH, Katherine, S. , FREDERICKSON, Shana , MARUYAMA, Toshiaki , LIN, Ying-Chi , RENSHAW, Mark
发明人： BOWDISH, Katherine, S. , FREDERICKSON, Shana , MARUYAMA, Toshiaki , LIN, Ying-Chi , RENSHAW, Mark
IPC分类号： C12P19/34
摘要： Methods of amplifying nucleic acid have now been discovered which include the steps of: a) annealing a primer to a template nucleic acid sequence, the primer having a first portion which anneals to the template and a second portion of predetermined sequence; b) synthesizing a polynucleotide that anneals to and is complementary to the portion of the template between the location at which the first portion of the primer anneals to the template and the end of the template, the polynucleotide having a first end and a second end, wherein the first end incorporates the primer; c) separating the polynucleotide synthesized in step (b ) from the template; d) annealing a nested oligonucleotide to the second end of the polynucleotide synthesized in step (b), the nested oligonucleotide having a first portion that anneals to the second end of the polynucleotide and a second portion having the same predetermined sequence as the second portion of the primer; e) extending the polynucleotide synthesized in step (b) to provide a terminal portion thereof that is complementary to the predetermined sequence; and f) amplifying the extended polynucleotide using a single primer having the predetermined sequence.

5. 发明申请

WO2005060641A2 ENGINEERED TEMPLATES AND THEIR USE IN SINGLE PRIMER AMPLIFICATION 审中-公开
标题翻译：工程模板及其在单一放大器中的使用
公开(公告)号：WO2005060641A2
公开(公告)日：2005-07-07
申请号：PCT/US2004/041945
申请日：2004-12-15
申请人： ALEXION PHARMACEUTICALS, INC. , MARUYAMA, Toshiaki , FREDERICKSON, Shana , BOWDISH, Katherine, S. , RENSHAW, Mark , LIN, Ying-Chi
发明人： MARUYAMA, Toshiaki , FREDERICKSON, Shana , BOWDISH, Katherine, S. , RENSHAW, Mark , LIN, Ying-Chi
IPC分类号： C07K16/00 , C07K16/08 , C07K16/42 , C12N15/10 , C12Q1/68
CPC分类号： C07K16/4291 , C07K16/005 , C07K16/082 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C12N15/1093 , C12Q1/6844 , C12Q1/6853 , C12Q1/6855 , C12Q1/686 , Y10S530/861 , C12Q2525/161 , C12Q2525/155 , C12Q2537/157 , C12Q2533/101 , C12Q2525/301 , C12Q2525/131 , C12Q2525/186
摘要： Methods of amplifying nucleic acid have now been discovered which include the steps of: a) annealing a primer to a template nucleic acid sequence, the primer having a first portion which anneals to the template and a second portion of predetermined sequence; b) synthesizing a polynucleotide that anneals to and is complementary to the portion of the template between the location at which the first portion of the primer anneals to the template and the end of the template, the polynucleotide having a first end and a second end, wherein the first end incorporates the primer; c) separating the polynucleotide synthesized in step (b) from the template; d) annealing a nested oligonucleotide to the second end of the polynucleotide synthesized in step (b), the nested oligonucleotide having a first portion that anneals to the second end of the polynucleotide and a second portion having the same predetermined sequence as the second portion of the primer; e) extending the polynucleotide synthesized in step (b) to provide a terminal portion thereof that is complementary to the predetermined sequence; and f) amplifying the extended polynucleotide using a single primer having the predetermined sequence.. In particularly useful embodiments, the methods are used to amplify a repertoire of IgA antibodies.
摘要翻译：现已发现扩增核酸的方法，其包括以下步骤：a）将引物退火至模板核酸序列，所述引物具有与模板退火的第一部分和预定序列的第二部分; b）合成在所述模板的第一部分与所述模板退火的位置与所述模板的末端之间退火并与所述模板部分互补的多核苷酸，所述多核苷酸具有第一末端和第二末端，其中所述第一端包含所述底漆; c）将步骤（b）中合成的多核苷酸与模板分离; d）将嵌套的寡核苷酸退火到步骤（b）中合成的多核苷酸的第二末端，所述嵌套的寡核苷酸具有与所述多核苷酸的第二末端退火的第一部分和具有与所述多核苷酸的第二部分相同的预定序列的第二部分底漆; e）延伸在步骤（b）中合成的多核苷酸以提供与预定序列互补的其末端部分; 和f）使用具有预定序列的单引物扩增延伸的多核苷酸。在特别有用的实施方案中，该方法用于扩增IgA抗体的所有组成成分。

6. 发明申请

WO2004050017A2 RATIONALLY DESIGNED ANTIBODIES 审中-公开
标题翻译：方案设计抗体
公开(公告)号：WO2004050017A2
公开(公告)日：2004-06-17
申请号：PCT/US2003/036894
申请日：2003-11-17
申请人： ALEXION PHARMACEUTICALS, INC.
发明人： BOWDISH, Katherine, S. , FREDERICKSON, Shana , RENSHAW, Mark
IPC分类号： A61K
CPC分类号： C07K14/505 , A61K2039/505 , C07K14/524 , C07K16/00 , C07K16/005 , C07K16/1282 , C07K16/18 , C07K16/46 , C07K2317/21 , C07K2317/55 , C07K2317/565 , C07K2319/00 , C07K2319/30
摘要： Antibodies or fragments thereof having at least two CDR regions replaced or fused with biologically active peptides are described. Compositions containing such antibodies or fragments thereof are useful in therapeutic and diagnostic modalities.
摘要翻译：描述了具有替换或与生物活性肽融合的至少两个CDR区的抗体或其片段。含有此类抗体或其片段的组合物可用于治疗和诊断方式。

7. 发明公开

EP1711615A2 ENGINEERED TEMPLATES AND THEIR USE IN SINGLE PRIMER AMPLIFICATION 审中-公开
标题翻译：工程模板及其在单一主放大中的使用
公开(公告)号：EP1711615A2
公开(公告)日：2006-10-18
申请号：EP04814163.4
申请日：2004-12-15
申请人： ALEXION PHARMACEUTICALS, INC.
发明人： MARUYAMA, Toshiaki , FREDERICKSON, Shana , BOWDISH, Katherine, S. , RENSHAW, Mark , LIN, Ying-Chi
IPC分类号： C12Q1/00
CPC分类号： C07K16/4291 , C07K16/005 , C07K16/082 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C12N15/1093 , C12Q1/6844 , C12Q1/6853 , C12Q1/6855 , C12Q1/686 , Y10S530/861 , C12Q2525/161 , C12Q2525/155 , C12Q2537/157 , C12Q2533/101 , C12Q2525/301 , C12Q2525/131 , C12Q2525/186
摘要： Methods of amplifying nucleic acid have now been discovered which include the steps of: a) annealing a primer to a template nucleic acid sequence, the primer having a first portion which anneals to the template and a second portion of predetermined sequence; b) synthesizing a polynucleotide that anneals to and is complementary to the portion of the template between the location at which the first portion of the primer anneals to the template and the end of the template, the polynucleotide having a first end and a second end, wherein the first end incorporates the primer; c) separating the polynucleotide synthesized in step (b) from the template; d) annealing a nested oligonucleotide to the second end of the polynucleotide synthesized in step (b), the nested oligonucleotide having a first portion that anneals to the second end of the polynucleotide and a second portion having the same predetermined sequence as the second portion of the primer; e) extending the polynucleotide synthesized in step (b) to provide a terminal portion thereof that is complementary to the predetermined sequence; and f) amplifying the extended polynucleotide using a single primer having the predetermined sequence. In particularly useful embodiments, the methods are used to amplify a repertoire of IgA antibodies.
摘要翻译：现在已经发现了扩增核酸的方法，其包括以下步骤：a）将引物与模板核酸序列退火，所述引物具有与模板退火的第一部分和预定序列的第二部分; b）合成与所述模板的所述部分退火并与所述模板的所述部分互补的多核苷酸，所述位置在所述引物的第一部分与所述模板退火的位置与所述模板的末端之间退火，所述多核苷酸具有第一末端和第二末端，其中第一末端包含引物; c）将步骤（b）中合成的多核苷酸与模板分离; d）将巢式寡核苷酸退火至在步骤（b）中合成的多核苷酸的第二末端，所述巢式寡核苷酸具有与多核苷酸的第二末端退火的第一部分和与第二部分具有相同预定序列的第二部分底漆; e）延伸步骤（b）中合成的多核苷酸以提供与预定序列互补的其末端部分; 和f）使用具有预定序列的单一引物扩增延伸的多核苷酸。在特别有用的实施方案中，所述方法用于扩增IgA抗体库。

8. 发明申请

WO2010042890A2 POLYPEPTIDES THAT BIND TRAIL-RI AND TRAIL-R2 审中-公开
标题翻译：聚合TRAIL-RI和TRAIL-R2的多聚体
公开(公告)号：WO2010042890A2
公开(公告)日：2010-04-15
申请号：PCT/US2009/060271
申请日：2009-10-09
申请人： ANAPHORE, INC. , BOWDISH, Katherine , KRETZ-ROMMEL, Anke , RENSHAW, Mark , LIN, Bing , WILD, Martha
发明人： BOWDISH, Katherine , KRETZ-ROMMEL, Anke , RENSHAW, Mark , LIN, Bing , WILD, Martha
IPC分类号： C07K7/00
CPC分类号： G01N33/6845 , A61K38/00 , C07K14/4726 , C07K2319/33 , C07K2319/70 , C07K2319/74
摘要： Agonists for TRAIL death receptors including polypeptides having a multimerizing, e.g. trimerizing, domain and a polypeptide sequence that binds to at least one of TRAIL death receptors TRAIL-Rl and TRAIL-R2. Agonists are described that do not bind to TRAIL decoy receptors. The multimerizing domain may be derived from human tetranectin. The agonists can induce apoptosis in pathogenic cells expressing a TRAIL death receptor. Pharmaceutical compositions are described for treating diseases associated with cells expressing DR4 and DR5, such as tumor cells. Methods for selecting polypeptides and preparing multimeric complexes.
摘要翻译：用于TRAIL死亡受体的激动剂包括具有多聚化的多肽，例如，三聚体，结构域和多肽序列，其结合至少一种TRAIL-R1和TRAIL-R2。描述了不结合TRAIL诱饵受体的激动剂。多聚化结构域可以衍生自人类tetranectin。激动剂可诱导表达TRAIL死亡受体的致病细胞凋亡。描述了用于治疗与表达DR4和DR5的细胞例如肿瘤细胞相关的疾病的药物组合物。选择多肽并制备多聚体复合物的方法。

9. 发明公开

EP1370589A2 RATIONALLY DESIGNED ANTIBODIES 有权
标题翻译：拉提纳尔DESIGNED抗体
公开(公告)号：EP1370589A2
公开(公告)日：2003-12-17
申请号：EP01985007.2
申请日：2001-12-05
申请人： ALEXION PHARMACEUTICALS, INC.
发明人： BOWDISH, Katherine, S. , BARBAS-FREDERICKSON, Shana , RENSHAW, Mark
IPC分类号： C07K19/00 , C12N15/62 , C12N15/70 , C12N1/21 , A61K39/395 , A61K39/00 , G01N33/50 , G01N33/573 , C07K14/475 , C07K14/505 , C07K16/00 , C12N15/13 , C07K16/12
CPC分类号： C07K14/505 , A61K39/00 , A61K39/40 , A61K2039/505 , C07K14/524 , C07K16/00 , C07K16/005 , C07K16/1282 , C07K16/18 , C07K16/46 , C07K2317/21 , C07K2317/55 , C07K2317/565 , C07K2317/74 , C07K2318/10 , C07K2319/00 , C07K2319/036 , C07K2319/30 , C07K2319/75 , C12N5/0641 , C12N2501/14 , C12N2506/11
摘要： Antibodies or fragments thereof having CDR regions replaced or fused with biologically active peptides are described. Flanking sequences may optionally be attached at one or both the carboxy-terminal and amino-terminal ends of the peptide in covalent association with adjacent framework regions. Compositions containing such antibodies or fragments thereof are useful in therapeutic and diagnostic modalities.

10. 发明申请

WO2011043834A1 COMBINATORIAL LIBRARIES BASED ON C-TYPE LECTIN DOMAIN 审中-公开
标题翻译：基于C型LECTIN域的组合图书馆
公开(公告)号：WO2011043834A1
公开(公告)日：2011-04-14
申请号：PCT/US2010/023803
申请日：2010-02-10
申请人： ANPHORE, INC , WILD, Martha , KRETZ-ROMMEL, Anke , BOWDISH, Katherine , RENSHAW, Mark
发明人： WILD, Martha , KRETZ-ROMMEL, Anke , BOWDISH, Katherine , RENSHAW, Mark
IPC分类号： C12N15/10 , C07K14/47
CPC分类号： C07K14/4726 , C12N15/1044
摘要： This invention relates to polypeptide libraries comprising polypeptides having a C-type lectin domain (CTLD) with a randomized loop region, as well as nucleic acid libraries comprising nucleic acid molecules encoding such polypeptides. The invention also relates to methods for generating the randomized polypeptides and the polypeptide libraries. The invention further relates to methods of screening the polypeptide and nucleic acid libraries based on the specific binding of the modified CTLDs to a target molecule of interest. The invention also relates to polypeptides derived from such libraries that bind to target molecules of interest.
摘要翻译：本发明涉及包含具有随机化环区的C型凝集素结构域（CTLD）的多肽的多肽文库以及包含编码这种多肽的核酸分子的核酸文库。本发明还涉及产生随机多肽和多肽文库的方法。本发明还涉及基于修饰的CTLD与目标靶分子的特异性结合来筛选多肽和核酸文库的方法。本发明还涉及衍生自与感兴趣的靶分子结合的这些文库的多肽。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式